Hyperthermia, thermotolerance and topoisomerase II inhibitors
Author:
Open Access
- 1 August 1995
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 72 (2) , 333-338
Abstract
The cytoxicity of both intercalating (m-AMSA) and non-intercalating (VP16, VM26) topoisomerase II-targeting drugs is thought to occur via trapping DNA topoisomerase II on DNA in the form of cleavable complexes. First, analysis of cleavable complexes (detected as DNA double-strand breaks) by pulsed-field gel electrophoresis confirmed the correlation between cleavable complex formation and cytotoxicity of three topoisomerase-targeting drugs in HeLa S3 cells (the order of effects being VM26 > m-AMSA > VP16). In contrast to many antineoplastic agents, hyperthermic treatments were found to protect cells against the toxicity of all three topoisomerase II drugs. Hyperthermia treatment does not alter drug accumulation but reduces the ability of the drug-topoisomerase II complex to form the cleavable complexes. Nuclear protein aggregation induced by heat at the sites of topoisomerase II-DNA interaction may explain such an effect. In thermotolerant cells, the toxic effects of VP16 but not m-AMSA were reduced. For both drugs, however, the status of thermotolerance did not affect cleavable complex formation by the drugs. Thus, protection against VP-16 toxicity seems not to be associated with heat-induced activation of the P-gp 170 pump or altered topoisomerase II-DNA interactions. Rather, a protective (heat shock protein mediated?) mechanism against non-intercalating topoisomerase II drugs seems to occur at a stage after DNA-drug interaction. Finally, heat treatment before topoisomerase II drug treatment reduced toxicity and cleavable complex formation in thermotolerant cells to about the same extent as in non-tolerant cells, consistent with the presumption of nuclear protein aggregation being responsible for this effect.Keywords
This publication has 29 references indexed in Scilit:
- Growth arrest of human B lymphocytes is accompanied by induction of the low molecular weight mammalian heat shock protein (Hsp28)The Journal of Immunology, 1992
- Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugsJournal of Molecular Biology, 1991
- Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein.1991
- REDUCED DNA BREAK FORMATION AND CYTO-TOXICITY OF THE TOPOISOMERASE-II DRUG 4'-(9'-ACRIDINYLAMINO)METHANESULFON-META-ANISIDIDE WHEN COMBINED WITH HYPERTHERMIA IN HUMAN AND RODENT CELL-LINES1989
- CHEF Electrophoresis, a Sensitive Technique for the Determination of DNA Double-strand BreaksInternational Journal of Radiation Biology, 1989
- TOPOISOMERASE-II-MEDIATED DNA DAMAGE PRODUCED BY 4'-(9-ACRIDINYLAMINO)-METHANESULFON-META-ANISIDIDE AND RELATED ACRIDINES IN L1210-CELLS AND ISOLATED-NUCLEI - RELATION TO CYTO-TOXICITY1988
- Heat shock proteins: role in thermotolerance, drug resistance, and relationship to DNA topoisomerases.1987
- The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)Biochemical and Biophysical Research Communications, 1986
- Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sitesCell, 1986
- Organization of the higher-order chromatin loop: specific DNA attachment sites on nuclear scaffoldCell, 1984